To further dissect the relevant clinical immunophenotype of the CD61+ T cells that may contribute toward enhanced cancer immunity and improved survival in patients with cancer, we performed multicolor flow cytometric profiling of tumors from 19 patients with NSCLC. This evidence concerns the gene ITGB3 and cancer.